相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Chromatin Remodeling Gene ARID1A Is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma
Zsuzsanna Lichner et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Phase II study of everolimus in metastatic urothelial cancer
Matthew I. Milowsky et al.
BJU INTERNATIONAL (2013)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Activation of HIF2 alpha in Kidney Proximal Tubule Cells Causes Abnormal Glycogen Deposition but not Tumorigenesis
Leiping Fu et al.
CANCER RESEARCH (2013)
Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer
Matthew D. Galsky et al.
CLINICAL GENITOURINARY CANCER (2013)
ICUD-EAU International Consultation on Bladder Cancer 2012: Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Maximilian Burger et al.
EUROPEAN UROLOGY (2013)
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder
Georgios Gakis et al.
EUROPEAN UROLOGY (2013)
ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers
Ashish M. Kamat et al.
EUROPEAN UROLOGY (2013)
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma-Neoadjuvant and Adjuvant Settings
Cora N. Sternberg et al.
EUROPEAN UROLOGY (2013)
Oncogenic FGFR3 gene fusions in bladder cancer
Sarah V. Williams et al.
HUMAN MOLECULAR GENETICS (2013)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
Arjun V. Balar et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
TSC1 involvement in bladder cancer: diverse effects andtherapeutic implications
Yanan Guo et al.
JOURNAL OF PATHOLOGY (2013)
Inhibition of mTORC2 but not mTORC1 Up-Regulates E-Cadherin Expression and Inhibits Cell Motility by Blocking HIF-2α Expression in Human Renal Cell Carcinoma
Shintaro Maru et al.
JOURNAL OF UROLOGY (2013)
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation
Payal Kapur et al.
LANCET ONCOLOGY (2013)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
Fibroblast growth factor receptor-3 in urothelial tumorigenesis
Gopa Iyer et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Advanced urothelial carcinoma: overcoming treatment resistance through novel treatment approaches
Richard M. Bambury et al.
FRONTIERS IN PHARMACOLOGY (2013)
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
D. Y. Heng et al.
ANNALS OF ONCOLOGY (2012)
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
A. J. Zurita et al.
ANNALS OF ONCOLOGY (2012)
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
E. Seront et al.
ANNALS OF ONCOLOGY (2012)
Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma
Sebastian Rogenhofer et al.
BJU INTERNATIONAL (2012)
Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma
G. Sonpavde et al.
BRITISH JOURNAL OF CANCER (2012)
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
Jenny J. Kim et al.
CANCER (2012)
Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch
N. Hayashi et al.
CELL DEATH AND DIFFERENTIATION (2012)
A Molecular Taxonomy for Urothelial Carcinoma
Gottfrid Sjodahl et al.
CLINICAL CANCER RESEARCH (2012)
mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy
Alejandro Gomez-Pinillos et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2012)
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors
Matthew D. Galsky et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma
Yu-Ning Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma
Sandra Rebouissou et al.
JOURNAL OF PATHOLOGY (2012)
Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers EDITORIAL COMMENT
Bas W. G. van Rhijn
JOURNAL OF UROLOGY (2012)
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
Andrea Necchi et al.
LANCET ONCOLOGY (2012)
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
Hai T. Tran et al.
LANCET ONCOLOGY (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma
Guangwu Guo et al.
NATURE GENETICS (2012)
BAP1 loss defines a new class of renal cell carcinoma
Samuel Pena-LlopiS et al.
NATURE GENETICS (2012)
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Annamaria Rapisarda et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Treatment selection in metastatic renal cell carcinoma: expert consensus
Bernard Escudier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C
X. Niu et al.
ONCOGENE (2012)
Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma
David Lindgren et al.
PLOS ONE (2012)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
New Therapeutic Challenges in Advanced Bladder Cancer
Joaquim Bellmunt et al.
SEMINARS IN ONCOLOGY (2012)
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2011)
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
F. R. Lamont et al.
BRITISH JOURNAL OF CANCER (2011)
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
Brian I. Rini et al.
CLINICAL CANCER RESEARCH (2011)
Anti-VEGF Treatment-Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype
Carmine Carbone et al.
CLINICAL CANCER RESEARCH (2011)
von Hippel-Lindau disease: A clinical and scientific review
Eamonn R. Maher et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2011)
Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours
Achim Fleischmann et al.
EUROPEAN UROLOGY (2011)
Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma
Hiroshi Hirata et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
Srikala S. Sridhar et al.
INVESTIGATIONAL NEW DRUGS (2011)
Individualizing Follow-Up for Patients With Early-Stage Melanoma
Vernon K. Sondak et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
Chun-Fang Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
Noah M. Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma
Betty Gardie et al.
JOURNAL OF MEDICAL GENETICS (2011)
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Ignacio Varela et al.
NATURE (2011)
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
Yaoting Gui et al.
NATURE GENETICS (2011)
Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
J. C. Welti et al.
ONCOGENE (2011)
A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1
Gottfrid Sjodahl et al.
PLOS ONE (2011)
Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas
Brendan D. Looyenga et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
Denise A. Chan et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Genetic and Functional Studies Implicate HIF1α as a 14q Kidney Cancer Suppressor Gene
Chuan Shen et al.
CANCER DISCOVERY (2011)
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
M. Lae et al.
ANNALS OF ONCOLOGY (2010)
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium
Daniel P. Petrylak et al.
BJU INTERNATIONAL (2010)
A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results
Raj S. Pruthi et al.
BJU INTERNATIONAL (2010)
Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome
David Lindgren et al.
CANCER RESEARCH (2010)
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion
Manoj Garg et al.
EUROPEAN JOURNAL OF CANCER (2010)
Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer
David J. Gallagher et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway
Christina Barbara Ching et al.
LABORATORY INVESTIGATION (2010)
Hsp27 Protects Adenocarcinoma Cells from UV-Induced Apoptosis by Akt and p21-Dependent Pathways of Survival
Ragu Kanagasabai et al.
MOLECULAR CANCER RESEARCH (2010)
Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB
Johanna C. Scheuermann et al.
NATURE (2010)
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Gillian L. Dalgliesh et al.
NATURE (2010)
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci
Nathaniel Rothman et al.
NATURE GENETICS (2010)
The genetic basis of kidney cancer: a metabolic disease
W. Marston Linehan et al.
NATURE REVIEWS UROLOGY (2010)
FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
Lucie C. Kompier et al.
PLOS ONE (2010)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Sian Jones et al.
SCIENCE (2010)
Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression
David J. McConkey et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102
G. K. Philips et al.
ANNALS OF ONCOLOGY (2009)
Phase 2 Trial of Sorafenib in Patients With Advanced Urothelial Cancer A Trial of the Eastern Cooperative Oncology Group
Robert Dreicer et al.
CANCER (2009)
A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma
Christian Wuelfing et al.
CANCER (2009)
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
Margaret A. Knowles et al.
CANCER AND METASTASIS REVIEWS (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney
Rameen Beroukhim et al.
CANCER RESEARCH (2009)
Hijacking the Chromatin Remodeling Machinery: Impact of SWI/SNF Perturbations in Cancer
Bernard Weissman et al.
CANCER RESEARCH (2009)
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
Fiona M. Platt et al.
CLINICAL CANCER RESEARCH (2009)
FGFR3 Mutations Indicate Better Survival in Invasive Upper Urinary Tract and Bladder Tumours
Johanna M. M. van Oers et al.
EUROPEAN UROLOGY (2009)
The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion - the prognostic contribution of related molecular markers
Julieta Afonso et al.
HISTOPATHOLOGY (2009)
Association of C-Terminal Ubiquitin Hydrolase BRCA1-Associated Protein 1 with Cell Cycle Regulator Host Cell Factor 1
Shahram Misaghi et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
The SWI/SNF complex and cancer
D. Reisman et al.
ONCOGENE (2009)
Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
Guru Sonpavde et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
Economic aspects of bladder cancer: what are the benefits and costs?
K. D. Sievert et al.
WORLD JOURNAL OF UROLOGY (2009)
HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma
John D. Gordan et al.
CANCER CELL (2008)
Hypermethylation of the 5′CpG island of the FHIT gene in clear cell renal carcinomas
Sergiy Kvasha et al.
CANCER LETTERS (2008)
Sensitivity to epidermal growth factor receptor inhibitor requires E-cedherin expression in urothelial carcinoma cells
Peter C. Black et al.
CLINICAL CANCER RESEARCH (2008)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
Breast Cancer Survivors and Hot Flashes: The Search for Nonhormonal Treatments
Nancy E. Avis
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
Toni K. Choueiri et al.
JOURNAL OF UROLOGY (2008)
Small-Molecule Inhibitors of HIF-2a Translation Link Its 5′UTR Iron-Responsive Element to Oxygen Sensing
Michael Zimmer et al.
MOLECULAR CELL (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
C-met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations
Steven F. Bellon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports
J. R. Toro et al.
JOURNAL OF MEDICAL GENETICS (2008)
Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors
Vera L. Costa et al.
BMC CANCER (2007)
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma:: Results of a multicenter phase II National Cancer Institute trial
Maha H. A. Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis
Y. Hori et al.
JOURNAL OF PATHOLOGY (2007)
Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma
Kyle A. Furge et al.
CANCER RESEARCH (2007)
Hereditary leiomyomatosis and renal cell cancer:: an unusual and aggressive form of hereditary renal carcinoma
Munir Al Refae et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
The hypoxia-inducible factor 2α N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo
Qin Yan et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells
Masayuki Kamada et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Superficial and muscle-invasive bladder cancer: Principles of management for outcomes assessments
Dipen J. Parekh et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors
Elena Lopez-knowles et al.
CANCER RESEARCH (2006)
HIF-2α regulates Oct-4:: effects of hypoxia on stem cell function, embryonic development, and tumor growth
KL Covello et al.
GENES & DEVELOPMENT (2006)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer:: Tesults of a randomized, multicenter, phase III trial (AUO-AB 05/95)
J Lehmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma
RR Raval et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
JE Nutt et al.
BRITISH JOURNAL OF CANCER (2004)
FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma
BSW van Rhijn et al.
CANCER RESEARCH (2004)
Applications of array technology:: identification of molecular targets in bladder cancer
M Sánchez-Carbayo et al.
BRITISH JOURNAL OF CANCER (2003)
Novel approaches with targeted therapies in bladder cancer - Therapy of bladder cancer by blockade of the epidermal growth factor receptor family
J Bellmunt et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2003)
On the role of Hsp27 in regulating apoptosis
CG Concannon et al.
APOPTOSIS (2003)
Inhibition of HIF2 alpha is sufficient to suppress pVHL-defective tumor growth
K Kondo et al.
PLOS BIOLOGY (2003)
Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma
ME Sanders et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron
SJ Mandriota et al.
CANCER CELL (2002)
The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma
JK Maranchie et al.
CANCER CELL (2002)
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
K Kondo et al.
CANCER CELL (2002)
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
C Billerey et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases
B Delahunt et al.
HUMAN PATHOLOGY (2001)
Hsp27 negatively regulates cell death by interacting with cytochrome c
JM Bruey et al.
NATURE CELL BIOLOGY (2000)
分享论文
